Login

Z.Z.N. Yiu

ORCID: 0000-0002-1831-074X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5022367999
Research Areas
  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical studies and practices
  • Asthma and respiratory diseases
  • Autoimmune Bullous Skin Diseases
  • Biosimilars and Bioanalytical Methods
  • Autoimmune and Inflammatory Disorders Research
  • Clinical practice guidelines implementation
  • COVID-19 Clinical Research Studies
  • Spondyloarthritis Studies and Treatments
  • Nonmelanoma Skin Cancer Studies
  • Allergic Rhinitis and Sensitization
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 and Mental Health
  • Drug-Induced Adverse Reactions
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Urticaria and Related Conditions
  • Cutaneous Melanoma Detection and Management
  • Complementary and Alternative Medicine Studies
  • Immunodeficiency and Autoimmune Disorders
  • Hidradenitis Suppurativa and Treatments
  • Inflammatory Bowel Disease
  • Meta-analysis and systematic reviews
  • Nail Diseases and Treatments

NIHR Manchester Biomedical Research Centre
 2017-2025

Manchester Academic Health Science Centre
 2016-2025

University of Manchester
 2016-2025

Manchester University NHS Foundation Trust
 2023-2025

Salford Royal Hospital
 2024

Northern Health and Social Care Trust
 2022-2024

The Christie NHS Foundation Trust
 2024

Salford Royal NHS Foundation Trust
 2014-2023

National Health Service
 2021-2023

National Institute for Health Research
 2020-2021

 Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
OPENALEX - Publications 
Richard B. Warren Catherine Smith Z.Z.N. Yiu Darren M. Ashcroft Juliet N. Barker and 7 more A. David Burden Mark Lunt Kathleen McElhone Anthony D. Ormerod Caroline Owen Nick J. Reynolds C.E.M. Griffiths

10.1038/jid.2015.208 article EN publisher-specific-oa Journal of Investigative Dermatology 2015-06-08
 British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
OPENALEX - Publications 
Catherine Smith Zarif K. Jabbar‐Lopez Z.Z.N. Yiu Tracy Bale A. David Burden and 34 more Laura C. Coates Maria Cruickshank T. Hadoke Eithne MacMahon Ruth Murphy Catherine Nelson‐Piercy Caroline Owen Richard Parslew Emilia Peleva E. Pottinger Eleanor J. Samarasekera Jill Stoddart C. Strudwicke Vanessa Venning Richard B. Warren L.S. Exton M.F. Mohd Mustapa P.M. McHenry Karen Gibbon D. Buckley T.A. Leslie Eleanor Mallon S. H. Wakelin S. Ungureanu R.Y.P. Hunasehally Michael J. Cork G.A. Johnston J. Natkunarajah F.S. Worsnop N. Chiang Gabriela Petrof J. Donnelly Clare Saunders A.G. Brain

Plain language summary available online

10.1111/bjd.15665 article EN British Journal of Dermatology 2017-05-17
 British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update
OPENALEX - Publications 
Catherine Smith Z.Z.N. Yiu Tracy Bale A. David Burden Laura C. Coates and 14 more W. Edwards Eithne MacMahon Satveer K. Mahil Arlene McGuire Ruth Murphy Catherine Nelson‐Piercy Caroline Owen Richard Parslew Olalekan A. Uthman Richard Woolf L. Manounah Martinsixtus Ezejimofor L.S. Exton M.F. Mohd Mustapa

Linked Comment:Ormerod. Br J Dermatol 2020; 183:604. Plain language summary available online

10.1111/bjd.19039 article EN British Journal of Dermatology 2020-03-19
 Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
OPENALEX - Publications 
Satveer K. Mahil Nick Dand K.J. Mason Z.Z.N. Yiu Teresa Tsakok and 95 more Freya Meynell Bola Coker Helen McAteer Lucy Moorhead Teena Mackenzie Mariateresa Rossi R. Rivera E. Mahé Andrea Carugno Michela Magnano Giulia Rech Esther A. Balogh Steven R. Feldman Claudia de la Cruz Siew Eng Choon Luigi Naldi Jo Lambert Phyllis I. Spuls D. Jullien H. Bachelez Devon E. McMahon Esther E. Freeman Paolo Gisondi L. Puig Richard B. Warren Paola Di Meglio Sinéad Langan Francesca Capon C.E.M. Griffiths Juliet N. Barker Catherine Smith Aadarsh Shah Alberto Barea Alberto Romero‐Maté Alekya Singapore Alexandra Paolino Alice Mwale Ana Maria Morales Callaghan A. J. Martinez Andrew J. DeCrescenzo Andrew Pink Ann Jones Ann Sergeant Annette Essex Anthony Bewley A. Makrygeorgou Astrid M. van Huizen Beatriz Pérez‐Suárez Farida Benhadou Birgitta Wilson Claréus Carla Tubau Prims Carrie L. Davis C. Quinlan Catriona Maybury Gonzalez A. Cesar Charlotte Barclay Claudio Greco Danielle Brassard Deanna Cummings Deepti Kolli V. Descamps Diana Ruíz Genao Efrossini Carras Elena B. Hawryluk Eliseo Martínez‐García Elżbieta Kłujszo Emily Dwyer Emmanuel Toni Enikö Sonkoly Enrique Loayza E. Daudén Fernando Valenzuela G Popov Georgie King Girard Celine Gloria Aparicio Graham A.R. Johnston Gustavo Anibal Cardozo Ian Pearson I. Yanguas Jamie Weisman Jennifer E. Carolan Jenny Hughes José María Ortiz Salvador J.M. Carrascosa Joseph J. Schwartz Karina Jackson Kathryn G. Kerisit K. Wu Leila Asfour Leontien de Graaf Cécile Lesort L. Meuleman Liv Eidsmo Lone Skov

10.1016/j.jaci.2020.10.007 article EN Journal of Allergy and Clinical Immunology 2020-10-16
 Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
OPENALEX - Publications 
Z.Z.N. Yiu G Becher Brian Kirby Philip Laws Nick J. Reynolds and 25 more Catherine Smith Richard B. Warren C.E.M. Griffiths Fiona Browne Ian Evans Elise Kleyn Linda Lawson Kathleen McElhone Teena Mackenzie Tess McPherson Ruth Murphy Caroline Owen Eleanor Pearson Josh Richards Mark Lunt A. David Burden Oras Alabas Simon Morrison Shernaz Walton Anthony Bewley Shehnaz Ahmed L. Jones Charlotte Symons Juliet N. Barker Philip Hampton

Drug survival of biologic therapies for psoriasis is a proxy longer-term treatment effectiveness and safety. Patient factors that are associated with the each differently (effect modifiers) may inform decision to choose between biologics.To assess drug safety commonly used biologics in UK Ireland identify effect modifiers these their survival.We conducted prospective cohort study patients using data from British Association Dermatologists Biologics Immunomodulators Register (BADBIR) November...

10.1001/jamadermatol.2022.2909 article EN JAMA Dermatology 2022-07-06
 Association of Lipid-Lowering Drugs With Risk of Psoriasis
OPENALEX - Publications 
Sizheng Steven Zhao Z.Z.N. Yiu Anne Barton John Bowes

Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to disease-modifying properties. However, large population-level studies scarce, causal interpretation results from traditional observational designs is limited by confounding.

10.1001/jamadermatol.2022.6051 article EN JAMA Dermatology 2023-01-25
 Demographics and disease characteristics of patients with psoriasis enrolled in the B ritish A ssociation of D ermatologists B iologic I nterventions R egister
OPENALEX - Publications 
Ireny Iskandar Darren M. Ashcroft Richard B. Warren Z.Z.N. Yiu Kathleen McElhone and 7 more Mark Lunt Juliet N. Barker A. David Burden Anthony D. Ormerod Nick J. Reynolds Catherine Smith C.E.M. Griffiths

The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in U.K. Republic Ireland.To describe demographics, disease severity comorbidities patients on enrolment into BADBIR, highlight differences those commencing biologics compared therapies.Baseline data were collected from 151 dermatology...

10.1111/bjd.13908 article EN British Journal of Dermatology 2015-05-18
 Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
OPENALEX - Publications 
Z.Z.N. Yiu K.J. Mason Philip Hampton Nick J. Reynolds Catherine Smith and 3 more Mark Lunt C.E.M. Griffiths Richard B. Warren

Real‐world biologic drug survival is an important proxy measure for effectiveness. Predictors of may help patients with psoriasis choose between therapies. (i) To assess the relative adalimumab, ustekinumab and secukinumab in psoriasis. (ii) investigate predictors survival. A prospective cohort study was performed British Association Dermatologists Biologics Immunomodulators Register (BADBIR) November 2007 August 2019. We analysis fitted a flexible parametric model discontinuation due to...

10.1111/bjd.18981 article EN cc-by British Journal of Dermatology 2020-03-03
 Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
OPENALEX - Publications 
Zara Izadi Erica J. Brenner Satveer K. Mahil Nick Dand Z.Z.N. Yiu and 95 more Mark Yates Ryan C. Ungaro Xian Zhang Manasi Agrawal Jean‐Frédéric Colombel Milena Gianfrancesco Kimme L Hyrich Anja Strangfeld Loreto Carmona Elsa F Mateus Saskia Lawson‐Tovey Eva Klingberg Giovanna Cuomo Marta Caprioli Ana Rita Cruz-Machado Carolina Mazeda Rebecca Hasseli Alexander Pfeil Hanns‐Martin Lorenz Bimba F. Hoyer Laura Trupin Stephanie Rush Patricia Katz Gabriela Schmajuk Lindsay Jacobsohn Andrea M. Seet Samar Al Emadi Leanna Wise Emily Gilbert Alí Duarte‐García Maria O. Valenzuela‐Almada C. A. Isnardi Rosana Quintana Enrique R. Soriano Tiffany Hsu Kristin M. D’Silva Jeffrey A. Sparks Naomi J. Patel Ricardo Machado Xavier Cláudia Diniz Lopes Marques Adriana María Kakehasi René‐Marc Flipo Pascal Claudepierre A. Cantagrel Philippe Goupille Zachary S. Wallace Suleman Bhana Wendy Costello Rebecca Grainger Jonathan S. Hausmann Jean W. Liew Emily Sirotich Paul Sufka Philip C. Robinson Pedro Machado C.E.M. Griffiths Juliet N. Barker Catherine Smith Jinoos Yazdany Michael D. Kappelman H. Bachelez Francesca Capon Bola Coker Claudia de la Cruz K.J. Mason Paola Di Meglio Joel M. Gelfand Paolo Gisondi Lars Iversen D. Jullien Jo Lambert Sinéad Langan Helen McAteer Freya Meynell Lucy Moorhead Luigi Naldi L. Puig Nick J. Reynolds Phyllis Spuls Tiago Torres Teresa Tsakok Alexandra Vincent Richard B. Warren H Waweru Siew C. Ng Richard B. Gearry Walter Reinisch Jean‐François Rahier James D. Lewis Gilaad G. Kaplan Flávio Steinwurz Michele Kissous-Hunt Irene Modesto Marishka Konings Brahim Dahou

<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...

10.1001/jamanetworkopen.2021.29639 article EN cc-by-nc-nd JAMA Network Open 2021-10-18
 Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR
OPENALEX - Publications 
K.J. Mason Juliet N. Barker Catherine Smith Philip Hampton Mark Lunt and 5 more Kathleen McElhone Richard B. Warren Z.Z.N. Yiu C.E.M. Griffiths A. David Burden

Patients with psoriasis enrolled in clinical trials of biologics may not be representative the real-world population. There is evidence that patients ineligible for such have a greater risk serious adverse events (SAEs), but effect on drug discontinuation and effectiveness are unknown.To determine whether (1) discontinuation, (2) effectiveness, (3) rates SAEs differ categorized as eligible or trials.An observational study using 157 dermatology centers United Kingdom Republic Ireland was...

10.1001/jamadermatol.2018.0183 article EN JAMA Dermatology 2018-03-28
 Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
OPENALEX - Publications 
Z.Z.N. Yiu Catherine Smith Darren M. Ashcroft Mark Lunt Shernaz Walton and 5 more Ruth Murphy Nick J. Reynolds Anthony D. Ormerod C.E.M. Griffiths Richard B. Warren

Serious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of serious infections biologics used to treat by comparison cohort non-biologic systemic therapies in propensity score-weighted Cox proportional hazards model using data from British Association Dermatologists Biologic Interventions Register. Overall, 1,352; 3,271; and 994 participants were included etanercept, adalimumab, ustekinumab cohorts, respectively, 3,421 cohort. A total 283...

10.1016/j.jid.2017.10.005 article EN cc-by Journal of Investigative Dermatology 2017-10-17
 Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
OPENALEX - Publications 
Ali Al‐Janabi Oras Alabas Z.Z.N. Yiu Amy C. Foulkes Stephen Eyre and 26 more Adnan R. Khan Nick J. Reynolds Catherine Smith C.E.M. Griffiths Richard B. Warren Philip Laws Shehnaz Ahmed Juliet N. Barker Anthoney Bewley Ian Evans Philip Hampton Olivia Hughes Brian Kirby Elise Kleyn Mark Lunt Teena Mackenzie Kathy McElhone Tess McPherson Simon Morrison Alexa R. Shipman Shernaz Walton Christina Ye Anja Strangfeld Girish Kumar Gupta Richard Weller Vera Zietemann

Importance Biologics used for plaque psoriasis have been reported to be associated with an atopic dermatitis (AD) phenotype, or paradoxical eczema, in some patients. The risk factors this are unknown. Objective To explore of eczema by biologic class and identify eczema. Design, Setting, Participants This prospective cohort study data from the British Association Dermatologists Immunomodulators Register adults treated biologics who were seen at multicenter dermatology clinics UK Ireland....

10.1001/jamadermatol.2023.4846 article EN cc-by JAMA Dermatology 2023-12-06
 Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
OPENALEX - Publications 
Pedro Machado Martin Schäfer Satveer K. Mahil Jean W. Liew Laure Gossec and 49 more Nick Dand Alexander Pfeil Anja Strangfeld Anne C. Regierer Bruno Fautrel Carla Gimena Alonso Carla Gonçalves Schahin Saad C.E.M. Griffiths Claudia Lomater Corinne Miceli‐Richard Daniel Wendling D. Alpizar-Rodriguez Dieter Wiek Elsa F Mateus Emily Sirotich Enrique R. Soriano Francinne Machado Ribeiro Felipe Omura F. R. Martins H. Santos Jonathan Dau Juliet N. Barker Jonathan S. Hausmann Kimme L Hyrich Lianne S. Gensler Lígia Silva Lindsay Jacobsohn Loreto Carmona Marcelo M. Pinheiro Marcos David Zelaya María de los Ángeles Severina Mark Yates Maureen Dubreuil Monique Gore‐Massy Nicoletta Romeo Nigil Haroon Paul Sufka Rebecca Grainger Rebecca Hasseli Saskia Lawson‐Tovey Suleman Bhana Thao Pham Tor Olofsson Wilson Bautista‐Molano Zachary S. Wallace Z.Z.N. Yiu Jinoos Yazdany Philip C. Robinson Catherine Smith

Objectives To investigate factors associated with severe COVID-19 in people psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Methods Demographic data, clinical characteristics outcome severity of adults PsO, PsA axSpA were obtained from two international physician-reported registries. A three-point ordinal scale was defined: no hospitalisation, hospitalisation (and death) death. ORs estimated using multivariable logistic regression. Results Of 5045 cases, 18.3%...

10.1136/ard-2022-223499 article EN cc-by-nc Annals of the Rheumatic Diseases 2023-02-14
 Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
OPENALEX - Publications 
Oras Alabas K.J. Mason Z.Z.N. Yiu Catherine Smith Richard B. Warren and 28 more C.E.M. Griffiths Juliet N. Barker Simon Morrison Anthony Bewley Ian Evans Christopher Griffiths Shehnaz Ahmed Brian Kirby Elise Kleyn Philip Laws Philip Hampton Oras Alabas Kathleen McElhone Z.Z.N. Yiu Teena Mackenzie Tess McPherson Ruth Murphy Anthony D. Ormerod Shernaz Walton Nick J. Reynolds Catherine Smith Alexa R. Shipman Christina Ye Olivia Hughes Richard B. Warren Richard Weller Girish Kumar Gupta Vera Zietemann

Abstract Background The current management of psoriasis does not differentiate between young and old patients in selecting the safest and/or most effective biologic. Objectives To explore effect age at treatment initiation response to biologics with moderate-to-severe UK Eire. Methods Data from registering British Association Dermatologists Biologics Immunomodulators Register (BADBIR) 2007-2024 on first course Tumour Necrosis Factor (TNF), interleukin (IL) 12/13, IL-17 IL-23 inhibitors (i)...

10.1093/bjd/ljaf017 article EN cc-by British Journal of Dermatology 2025-01-10
Coming Soon ...